Pete and I are focused on attracting UHNW (ultra-high net worth investors) and family offices for the interim term and continue to build the relationships with institutional and pharma that will pay off in the mid to long term. Retail will continue to be a focus, but until interest rates turn, retail is not a investor category with a lot of spare cash.
There is a very interesting arbitrage opportunity in RAC at the moment that has a lot of parallels with what happened with CU6 and GenesisCare. This opportunity is of interest to a much wider pool of investors than those that invest in speculative biotechs.
RAC - Charts & Price Action, page-19058
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
0.030(2.11%) |
Mkt cap ! $247.1M | |||
| Open | High | Low | Value | Volume |
| $1.43 | $1.45 | $1.40 | $163.8K | 115.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $1.44 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.45 | 31396 | 1 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |